Immuneering (NASDAQ:IMRX - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Several other research analysts have also recently weighed in on the stock. UBS Group set a $14.00 price target on shares of Immuneering in a report on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immuneering in a report on Monday, September 21st. Chardan Capital raised shares of Immuneering to a "strong-buy" rating in a report on Monday, August 3rd. Mizuho set a $11.00 price objective on shares of Immuneering in a research report on Thursday, October 29th. Finally, HC Wainwright reissued a "buy" rating on shares of Immuneering in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.67.
Get Our Latest Report on IMRX
Immuneering Trading Down 2.0%
Shares of IMRX opened at $3.38 on Friday. The stock's 50-day moving average price is $3.88 and its two-hundred day moving average price is $4.70. Immuneering has a 12 month low of $3.29 and a 12 month high of $8.48. The company has a market capitalization of $218.89 million, a PE ratio of -3.28 and a beta of 0.49.
Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.06). Equities research analysts predict that Immuneering will post -1.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Immuneering
Large investors have recently made changes to their positions in the stock. American Century Companies Inc. boosted its position in Immuneering by 15.4% in the 3rd quarter. American Century Companies Inc. now owns 68,751 shares of the company's stock worth $282,000 after purchasing an additional 9,193 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Immuneering by 530.9% during the third quarter. Goldman Sachs Group Inc. now owns 607,011 shares of the company's stock worth $2,486,000 after buying an additional 510,791 shares in the last quarter. Empowered Funds LLC purchased a new position in Immuneering in the 3rd quarter worth approximately $302,000. Kovack Advisors Inc. acquired a new position in Immuneering during the third quarter worth $144,000. Finally, Palumbo Wealth Management LLC grew its holdings in shares of Immuneering by 51.6% in the third quarter. Palumbo Wealth Management LLC now owns 28,932 shares of the company's stock valued at $118,000 after purchasing an additional 9,849 shares during the period. 67.65% of the stock is owned by hedge funds and other institutional investors.
About Immuneering
(
Get Free Report)
Immuneering Corporation is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers. Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.